MediWound (NASDAQ:MDWD) COO Shmuel Hess Sells 1,865 Shares

MediWound Ltd. (NASDAQ:MDWD) COO Shmuel Hess sold 1,865 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $13.00, for a total transaction of $24,245.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shmuel Hess also recently made the following trade(s):

• On Thursday, August 27th, Shmuel Hess sold 3,958 shares of MediWound stock. The stock was sold at an average price of $12.92, for a total transaction of $51,137.36.

MediWound Stock Down 4.4%

NASDAQ MDWD opened at $12.66 on Friday. The stock has a market capitalization of $162.68 million, a P/E ratio of -7.03 and a beta of 0.15. MediWound Ltd. has a 52-week low of $12.52 and a 52-week high of $20.30. The firm has a 50-day moving average price of $14.16 and a 200 day moving average price of $15.64.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. The firm had revenue of $3.09 million during the quarter, compared to analyst estimates of $2.59 million. On average, equities research analysts expect that MediWound Ltd. will post -2.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MDWD. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of MediWound in a research report on Thursday, May 28th. Oppenheimer restated an “outperform” rating and set a $30.00 target price (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. Finally, Wall Street Zen cut shares of MediWound from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, MediWound presently has an average rating of “Hold” and a consensus target price of $33.00.

Institutional Trading of MediWound

Several large investors have recently modified their holdings of the business. Kotler Kevin purchased a new position in shares of MediWound during the 4th quarter worth approximately $6,225,000. Millennium Management LLC lifted its stake in MediWound by 355.6% in the 3rd quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock valued at $3,160,000 after buying an additional 136,884 shares in the last quarter. UBS Group AG grew its holdings in MediWound by 90.1% during the 4th quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company’s stock valued at $2,678,000 after buying an additional 68,756 shares during the last quarter. Sphera Funds Management LTD. grew its holdings in MediWound by 24.3% during the 4th quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company’s stock valued at $4,252,000 after buying an additional 45,077 shares during the last quarter. Finally, Summit Financial LLC increased its position in MediWound by 200.1% during the fourth quarter. Summit Financial LLC now owns 47,998 shares of the biopharmaceutical company’s stock worth $886,000 after buying an additional 32,006 shares in the last quarter. 46.83% of the stock is currently owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.